IRIS
DELLA PORTA, MATTEO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.379
AS - Asia 2.536
EU - Europa 1.107
SA - Sud America 584
AF - Africa 186
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.810
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.253
SG - Singapore 1.469
CN - Cina 656
BR - Brasile 509
FI - Finlandia 282
IE - Irlanda 199
NG - Nigeria 159
IT - Italia 113
DE - Germania 98
HK - Hong Kong 97
FR - Francia 94
CA - Canada 82
VN - Vietnam 78
GB - Regno Unito 73
NL - Olanda 67
SE - Svezia 55
IN - India 54
TR - Turchia 38
MX - Messico 28
JP - Giappone 27
ES - Italia 23
AR - Argentina 20
IQ - Iraq 19
PL - Polonia 19
BE - Belgio 18
RU - Federazione Russa 16
EC - Ecuador 13
ZA - Sudafrica 13
BD - Bangladesh 12
AU - Australia 10
IR - Iran 10
CL - Cile 9
PY - Paraguay 9
SA - Arabia Saudita 9
CO - Colombia 8
ID - Indonesia 8
PK - Pakistan 8
UA - Ucraina 8
KR - Corea 7
AT - Austria 6
CH - Svizzera 6
PE - Perù 6
UZ - Uzbekistan 6
VE - Venezuela 6
JO - Giordania 5
AE - Emirati Arabi Uniti 4
CZ - Repubblica Ceca 4
EG - Egitto 4
IL - Israele 4
JM - Giamaica 4
KZ - Kazakistan 4
LT - Lituania 4
NZ - Nuova Zelanda 4
DK - Danimarca 3
GR - Grecia 3
MA - Marocco 3
NO - Norvegia 3
PH - Filippine 3
TH - Thailandia 3
UY - Uruguay 3
BB - Barbados 2
BG - Bulgaria 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
EU - Europa 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
MY - Malesia 2
NP - Nepal 2
OM - Oman 2
PA - Panama 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
KE - Kenya 1
KH - Cambogia 1
KW - Kuwait 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
ML - Mali 1
MR - Mauritania 1
NI - Nicaragua 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
Totale 10.809
Salva come PNG Salva come JPEG
Città #
Wilmington 1.026
Chandler 954
Singapore 478
The Dalles 404
Shanghai 368
San Mateo 356
Helsinki 282
Ann Arbor 246
Ashburn 207
Dallas 205
Dublin 198
Boardman 186
Leawood 165
Benin City 159
Lawrence 159
Princeton 159
Beijing 137
Woodbridge 121
New York 115
Fairfield 101
Hong Kong 87
Paris 87
Amsterdam 60
São Paulo 50
Houston 42
Toronto 42
Seattle 38
Los Angeles 36
Milan 35
London 34
Council Bluffs 26
Santa Clara 25
Tokyo 24
Cambridge 23
Falls Church 23
Norwalk 23
Hanoi 21
Ho Chi Minh City 19
San Diego 19
Brussels 18
Kocaeli 18
San Francisco 18
Boston 17
Columbus 17
Redwood City 17
Monmouth Junction 15
Warsaw 15
Belo Horizonte 14
Montreal 14
Rio de Janeiro 14
Brooklyn 13
Phoenix 13
Stockholm 13
Redmond 11
Brasília 10
Curitiba 9
Pune 9
Tappahannock 9
Guangzhou 8
Mexico City 8
Haiphong 7
Naples 7
San Jose 7
Ankara 6
Atlanta 6
Baghdad 6
Charlotte 6
Chennai 6
Chicago 6
Guarulhos 6
Mumbai 6
New Delhi 6
São José do Rio Preto 6
Vancouver 6
Abbiategrasso 5
Amman 5
Des Moines 5
Genoa 5
Hangzhou 5
Johannesburg 5
Pittsburgh 5
Quito 5
Ribeirão Preto 5
Tashkent 5
Assago 4
Asunción 4
Campinas 4
Campo Grande 4
Chengdu 4
Falkenstein 4
Frankfurt am Main 4
Goiânia 4
Guayaquil 4
Hillah 4
Istanbul 4
João Pessoa 4
Kingston 4
Lima 4
Maceió 4
Miami 4
Totale 7.221
Salva come PNG Salva come JPEG
Nome #
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 197
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun. 2015 Jan 9;6:5901. 124
Costimulatory molecules and immune checkpoints are differentially expressed on different subsets of dendritic cells 104
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group 102
Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. 100
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 93
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 93
CD34 and CD2 expression in acute promyelocytic leukemia. 87
Clinical Effects of Driver Somatic mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With allogeneic Hematopoietic Stem-Cell Transplantation 86
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 86
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML 83
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? 78
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 77
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years 77
A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data. 76
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006 Nov 1;107(9):2206-11. PubMed PMID: 16998940. 76
Classification and prognostic evaluation of myelodysplastic syndromes 74
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 74
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 74
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 73
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) 72
Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL). 72
Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications. 71
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 70
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. 70
Importance of classical morphology in the diagnosis of myelodysplastic syndrome. 70
Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. 70
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes 70
Dendritic cells in acute promyelocytic leukaemia. 69
Prognosis of secondary acute myeloid leukemia 69
Multicenter validation of a simplified method for paroxysmal nocturnal hemoglobinuria screening. 69
Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors. 69
Leukemic transformation of polycythemia vera: a single center study of 23 patients 68
Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule. 68
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 68
THE IMPACT OF THE DEGREE OF ANEMIA ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME. A BASIS FOR PROGNOSTIC ASSESSMENT AND CLINICAL DECISION MAKING 68
Alterata espressione dei canali del Ca2+ in cellule progenitrici endoteliali di pazienti affetti da carcinoma cellulare renale, mielofibrosi idiopatica e tumore della mammella 68
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes 67
An unusual clinical presentation of multiple myeloma with involvement of the oro-pharynx. 66
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. 66
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 66
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised international prognostic scoring system (IPSS-R) 66
Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. 65
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival 65
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 64
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. 64
Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. 64
Simian virus 40 and lymphoproliferative disorder. 64
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience. 64
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 64
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders 64
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. 64
Sequence variations in mitochondrial ferritin: distribution in healthy controls and different types of patients. 63
Multicentre validation of a reproducible flow cytometric score for the diagnosis of low-risk myelodysplastic syndromes: results of a European LeukemiaNET study. 63
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 63
Myelodysplastic syndromes and bone marrow microenvironment. 63
Clinical evaluation of extra-hematological comorbidity in myelodysplastic syndromes: "ready-to-wear" versus "made-to-measure" tools. 63
High resolution melting for the identification of mutations in the iron responsive element of the ferritin light chain gene. 62
Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia 62
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet 62
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 62
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 61
27P * Common gene signature expressed by breast and kidney cancers-derived endothelial colony forming cells 61
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. 60
Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. 60
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome 60
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide 60
Differentiation of follicular dendritic sarcoma cells into functional myeloid-dendritic cell-like elements. 60
Novel trial designs for high-risk myelodysplastic syndromes. 59
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 59
Prognostic models in myelodysplastic syndromes 58
Treatment of anemia with erythroid stimulating agents in myelodysplastic syndromes. 58
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 58
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome 58
Role of the molecular staging and response in the management of follicular lymphoma patients. 58
VASCULAR ENDOTHELIAL GROWTH FACTOR OVEREXPRESSION IN BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME: BIOLOGICAL AND CLINICAL RELEVANCE 58
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. 58
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. 58
Clinical and biological implications of driver mutations in myelodysplastic syndromes 57
Second primary malignancies in ruxolitinib-treated myelofibrosis: Real-world evidence from 219 consecutive patients 57
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 56
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 56
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell–Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients 56
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 56
Involvement of the region 13q14 in a patient with admantinoma of the long bones 56
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. 56
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 56
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 56
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study 55
Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells. 55
Morphological features and prognostic implication in a retrospective analysis of 370 patients with myelodysplastic syndrome 55
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome 55
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. 55
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 55
Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens. 55
The effect of transfusion dependency and secondary iron overload on survival of patients with myelodysplastic syndrome 55
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 55
Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need 54
Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. 54
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study 53
Totale 6.773
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.618
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.618
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.635 0 0 0 0 0 531 242 104 360 220 16 162
2021/20221.059 70 12 24 213 23 26 29 132 105 70 323 32
2022/20232.634 374 85 210 325 252 237 5 234 493 210 176 33
2023/20241.356 121 178 278 47 27 115 57 149 20 46 167 151
2024/20252.000 58 51 24 42 22 275 77 238 255 511 234 213
2025/20262.052 880 275 253 433 179 32 0 0 0 0 0 0
Totale 10.941